Related references
Note: Only part of the references are listed.Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature
Jeffrey S. Berger et al.
AMERICAN HEART JOURNAL (2012)
Executive Summary Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Gordon H. Guyatt et al.
CHEST (2012)
Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2011)
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Christian W. Hamm et al.
EUROPEAN HEART JOURNAL (2011)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel
N. S. Kirkby et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation
P. C. J. Armstrong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Christian W. Hamm et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers
Kathleen Butler et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
Renli Teng et al.
DRUG METABOLISM AND DISPOSITION (2010)
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
Renli Teng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry
Henrik Sillen et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y(12) antagonists by using multiple electrode aggregometry
Sandra M. Penz et al.
THROMBOSIS JOURNAL (2010)
Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist
Steen Husted et al.
CARDIOVASCULAR THERAPEUTICS (2009)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
LANCET (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease
Rehan Qayyum et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y12 receptor antagonist, compared with clopidogral in patients with acute coronary syndrome
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Aspirin dose for the prevention of cardiovascular disease - A systematic review
Charles L. Campbell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin
S Husted et al.
EUROPEAN HEART JOURNAL (2006)
Platelet-active drugs - The relationships among dose, effectiveness, and side effects
C Patrono et al.
CHEST (2001)
Share Paper
